Skip to main content

Cannabix Technologies announces Stock Option Grant and Director Resignation

Cannabix Technologies Inc. - GlobeNewswire - Fri Mar 14, 2025

VANCOUVER, British Columbia, March 14, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) reports it is granting 3,375,000 incentive stock options to officers, directors and consultants of the Company, exercisable at $0.54 per share for five years, of which 650,000 will expire in two years and will be subject to vesting provisions.

In addition, the Company reports that Thomas Clarke has resigned as a Director of the Company. The Company thanks Mr. Clarke for his contributions and wishes him well in his future endeavours.

The Company has engaged InvestorsHub.com Inc. (“InvestorsHub”) for news release dissemination services for a fee of $20,000 USD effective May 14, 2025 until the budget is exhausted. The Company may elect to renew the engagement in the future. Consideration paid to InvestorsHub does not include any securities of the Company (address: PO Box 780, Harrisonville, MO 6470, 888-498-5839).

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


Primary Logo

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).